| Cat.No. | Name | Information |
|---|---|---|
| M6098 | Baicalein | Baicalein is a CYP2C9 and prolyl endopeptidase inhibitor, IC50 value of 3.12 mM. |
| M9325 | EGTA | EGTA is a specific calcium chelator with a Kd of 60.5 nM at physiological pH (7.4) and a high specificity for Ca2+ than for Mg2+.EGTA significantly inhibits the substrate adhesion capacity of inflammatory macrophages. |
| M9330 | Brij-35 | Brij-35 (Polidocanol) is a high HLB, ethoxylated, nonionic ether of lauryl alcohol with broad pH stability. |
| M6154 | 2-PMPA tetrasodium | 2-PMPA (PMPA tetrasodium salt) is a potent and selective inhibitor of glutamate carboxypeptidase II (GCPII) with an IC50 of 300 pM. |
| M2250 | Pamidronate disodium | Pamidronate disodium is a nitrogen containing bisphosphonate, used to the research of preventing osteoporosis. |
| M9916 | DPPH | DPPH (2,2-Diphenyl-1-picrylhydrazyl) is a stable free radical that measures the free radical scavenging activity of antioxidants. |
| M9194 | Insulin (human) | Insulin (human) is a polypeptide hormone that regulates the level of sugar (glucose) in the blood and is produced by beta cells of islets. |
| M3409 | Formestane | Formestane is a second generation selective aromatase inhibitor with an IC50 of 80 nM. |
| M9665 | N-(2-amino-2-oxoethyl)acrylamide | N-(2-Amino-2-oxoethyl)acrylamide |
| M7791 | Exo-1 | Exo1 is a reversible inhibitor of exocytosis, also a Golgi ARF 1 (ADP-Ribosylation Factor) GTPase activator. |
| M25051 | Alsevalimab | Alsevalimab is a human monoclonal antibody against B7-H4. |
| M25047 | Sabatolimab | Sabatolimab (MBG453) is a high-affinity, humanized, IgG4 (S228P) antibody targeting TIM-3, an inhibitory receptor that regulates adaptive and innate immune responses. Sabatolimab is a potential immunosuppression agent that can target TIM-3 on immune and myeloid cells. |
| M25037 | Cevostamab | Cevostamab (BFCR4350A; RG6160; RO7187797) is a humanized IgG1-based BsAb that targets membrane-proximal extracellular domain of FcRH5 on multiple myeloma (MM) cells as well as CD3 on T cells. Moreover, Cevostamab facilitates efficient synapse formation, improves killing activity of T cells against MM tumor cells. |
| M25027 | Bepranemab | Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research. |
| M25020 | Lulizumab | Lulizumab (Humanized Anti-CD28 Recombinant Antibody) is a selective CD28 blockade, Lulizumab prevents T cell activation by selectively targeting CD28 signaling. |
| M25014 | Mirzotamab | Mirzotamab is an IgG1κ antibody targeting to CD276/B7-H3. Mirzotamab can conjugates with Clezutoclaxum is a targeted antibody drug conjugate (ADC). |
| M25006 | Giloralimab | Giloralimab (ABBV-927) is a potent antiCD40 agonistic monoclonal antibody. Giloralimab has the potential for the research of cancer. |
| M25004 | Tinurilimab | Tinurilimab (Bay 1834942) is an anti-CEACAM6 monoclonal antibody. CEACAM6 is an immune checkpoint regulator suppressing the activity of effector T-cells against tumors. |
| M25003 | Talquetamab | Talquetamab (JNJ-64407564) is a potentially first-in-class humanized IgG4ҡ/λ bispecific antibody that binds to GPRC5D (G-protein-coupled receptor family, group C5, member D) and CD3, and induces T-cell-mediated by T-cell recruitment and activation. killing of GPRC5-expressing MM cells through T cell recruitment and activation.Talquetamab (JNJ-64407564) has antitumor activity. |
| M24990 | Nipocalimab | Nipocalimab (M281) is a fully human, recombinant, aglycosylated IgG1 monoclonal antibody. Nipocalimab is a human deglycosylated IgG1 anti-FcRn monoclonal antibody that binds with picomolar affinity to Fc receptor (FcRn) at both endosomal pH 6.0 and extracellular pH 7.6. |
| M24982 | Felzartamab | Felzartamab (MOR-202) is a human monoclonal antibody that targets CD38 and can be used in multiple myeloma research. |
| M24980 | Labetuzumab | Labetuzumab is a humanised anti-carcinoembryonic antigen (CEA) monoclonal antibody that inhibits tumour growth and sensitises human medullary thyroid cancer xenografts to Dacarbazine chemotherapy. |
| M24979 | Batoclimab | Batoclimab is a human anti-FcRn monoclonal antibody. Batoclimab can be used for the research of autoimmune diseases mediated by pathogenic IgG antibodies. |
| M24978 | Lacutamab | Lacutamab (IPH4102) is a humanized monoclonal antibody (mAb) directed against the immune receptor molecule KIR3DL2, produced by recombinant technology in CHO cells. Lacutamab can be used in research of cutaneous T-cell lymphoma. |
| M24969 | Magrolimab | Magrolimab (Hu5F9-G4) is a first-in-class humanized anti-CD47 IgG4 antibody with an anti-tumor activity. |
| M24962 | Semorinemab | Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease. |
| M24950 | Bivatuzumab | Bivatuzumab (Anti-CD44 Recombinant Antibody; BIWA 4) is a humanized monoclonal antibody directed against CD44v6. CD44v6 could acts as a sarcoma target for CAR-redirected CIK cells. |
| M24935 | Oregovomab | Oregovomab (Alt-2 monoclonal antibody) is a murine mAb targeting CA125. Oregovomab induces cytotoxic immune response against CA125 expressing tumor cells. |
| M24930 | Fianlimab | Fianlimab (REGN3767) is a human monoclonal antibody that targets the immune checkpoint receptor LAG-3 on T cells and has anti-tumour activity. |
| M24926 | Tilogotamab | Tilogotamab (GEN-1029) is an agonistic hexamer formation-enhanced mixture of two antibodies that target two separate epitopes on death receptor type 5 (DR5). Tilogotamab specifically binds to and activates DR5. Tilogotamab can be used for the research of multiple myeloma (MM). |
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
